Laquinimod is primarily used in the treatment of multiple sclerosis (MS), particularly relapsing-remitting forms of the disease. It helps reduce the frequency of relapses and slows the progression of disability by modulating the immune system. The compound crosses the blood-brain barrier and exerts anti-inflammatory effects within the central nervous system, helping to protect neurons and myelin from immune-mediated damage. It has also shown potential in preclinical studies for other neurodegenerative conditions, such as Huntington’s disease and Alzheimer’s disease, due to its neuroprotective properties. Clinical development has focused on its oral administration as a convenient, long-term therapy for chronic neurological disorders.